Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: AbbVie Inc (NYSE:ABBV) , UnitedHealth Group Inc. (NYSE:UNH), Gilead Sciences, Inc.(NASDAQ:GILD), Dendreon Corporation(NASDAQ:DNDN)
AbbVie Inc (NYSE:ABBV) managed to keep its gain at 0.93% on above-normal volume of 10.50 million shares. The stock settled at $47.84 after floating in a range of $47.33 to $48.00. Its latest price was $47.84, reaching market capitalization of $75.85million. Its 52-week range has been $32.51 to $48.42. AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals.
What was the Moving Force behind ABBV On Bullish Run? Read This Research Report on ABBV
UnitedHealth Group Inc. (NYSE:UNH) traded down on a volume of 9.09 million, higher than its standard daily volume. Shares have dropped -0.38% to $70.57. Over the last twelve months, the stock has added 30.08% and faced a worst price of $70.40. UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. The company?s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for large national employers.
Has UNH Found The Bottom And Ready To Gain Momentum? Find Out Here
Gilead Sciences, Inc.(NASDAQ:GILD) settled -0.72% lower at $63.86on above-normal volume of 9.08 million shares during the last trading day. The stock has its 12-month high at $32.07 and 52-week low price was $64.74. It traded in a range of $63.80 to $64.48 during the last trading day. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia
Why Should Investors Buy GILD After the Recent Fall ? Just Go Here and Find Out
Dendreon Corporation(NASDAQ:DNDN) saw its price fall on below-normal volume, as 10.80 million shares changed hands when compared with its average daily volume of 5.49 million shares. The stock was down -4.98% to $3.05. It has fallen over the last 12 months, dropping -35.59% and marked new low $3.01. Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients
Will DNDN Get Buyers Even After The Recent Rally? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)